The use of β3-adrenergic receptor agonists in the treatment of heart failure

Current Opinion in Investigational Drugs

Volumn 10, Issue 9, 2009, Pages 955-962

  Rasmussen, H H ^a,b   Figtree, G A ^b   Krum, H ^c   Bundgaard, H ^d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiac contractility; Intracellular Na+; Moxonidine; Na + K+ pump; Norepinephrine; Oxidative signaling

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CAPTOPRIL; METOPROLOL; MOXONIDINE; NEBIVOLOL; NITROPRUSSIDE SODIUM; SODIUM; SPIRONOLACTONE; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; EX VIVO STUDY; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HUMAN; IN VIVO STUDY; MUSCLE CELL; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; UPREGULATION; ANIMAL; DRUG EFFECT; GENETICS; HEART CONTRACTION; METABOLISM;

ADRENERGIC BETA-AGONISTS; ANIMALS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; RECEPTORS, ADRENERGIC, BETA-3;

EID: 69649102544     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 3-AR that have exhibited efficacy in humans.
2. 3 and atypical β- adrenoceptors. Med Res Rev (1993) 13(6):663-729.
3. 3-AR, thus confirming this 'atypical' receptor, which had previously been identified on the basis of pharmacological studies only as a molecular entity.
4. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev (1994) 46(2):121-136. (Pubitemid 24984776)
5. 3-adrenergic receptor. Annu Rev Pharmacol and Toxicol (1997) 37(1): 421-450.
6. 3-AR in the cardiovascular system. The importance of species dependence on the receptor structure, function and pharmacology is highlighted.
7. 3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol (2008) 378(2):225-240.
8. 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol (1996) 117(5):907-913.
9. 3-adrenoceptors. Br J Clin Pharmacol (1996) 42(3):291-300.
10. 3- adrenoceptor-mediated effect. Eur J Pharmacol (1998) 253(2-3):281-287.
11. 3-adrenoceptor agonists in rat myometrium and urinary bladder. European Journal of Pharmacology (2007) 573(1-3):184-189.
12. 3-AR in the heart and describing the negative inotropic effect mediated. Describes key pharmacological properties of the receptor in the human heart.
13. 3-adrenoceptors. Exp Physiol (2009) 94(4):400-411.
14. 3-AR upregulation in patients with heart failure. The study has important has been the foundation for many subsequent studies, including those that reproduced the results in animal models.
15. 3- adrenoceptor. Cardiovasc Res (2003) 59(2):262-265.
16. 3- adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev (2002) 20(1):19-26.
17. 3-Adrenergic stimulation in the human heart: Signal transduction, functional implications and therapeutic perspectives. Pharmazie (2006) 61(4):255-260.
18. 3-Adrenoceptor: Friend or foe? Heart Rhythm (2005) 2(12):1356-1358.
19. 3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart (Circ Physiol) (2004) 286(6): H2425-2433.
20. 3- adrenoceptor deficiency. Pflugers Arch (2007) 453(4):443-453.
21. Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M: Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol (2003) 91(9A):18F-40F. (Pubitemid 36555737)
22. 3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther (2005) 315(3):1203-1211.
23. Shattock MJ, Bers DM: Rat vs. rabbit ventricle: Ca flux and intracellular Na assessed by ion-selective microelectrodes. Am J Physiol (1989) 256(4 Pt 1):C813-822.
24. Bers DM, Bridge JH: Effect of acetylstrophanthidin on twitches, microscopic tension fluctuations and cooling contractures in rabbit ventricle. J Physiol (1988) 404:53-69.
25. 2+ handling in heart failure.
26. Pieske B, Houser SR: [Na+]i handling in the failing human heart. Cardiovasc Res (2003) 57(4):874-886. • A comprehensive review of the pathophysiology of excitation-contraction coupling in heart failure, including the role of increased levels of intracellular Na+. (Pubitemid 36324593)
27. Pogwizd SM, Sipido KR, Verdonck F, Bers DM: Intracellular Na in animal models of hypertrophy and heart failure: Contractile function and arrhythmogenesis. Cardiovasc Res (2003) 57(4):887-896. (Pubitemid 36324594)
28. + pump via effects on angiotensin metabolism. Am J Physiol (1996) 271 (1 Pt 1):C172-C180.
29. + pump. Circ Res (2000) 86(1):37-42.
30. + pump in isolated rabbit cardiac myocytes. J Physiol (2005) 565(3):815-825.
31. 1 pump subunit in cardiac myocytes. Abstr 12th International ATPase Conference (2008): Abs 156.
32. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, Agha SA, Rashad MA, Waheed S, Laskar S, Smith AL, Butler J: Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circulation (Heart Failure) (2009) 2(2):90-97.
33. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE et al: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 352(3):225-237. (Pubitemid 40110811)
34. + pump in rabbit cardiac myocytes after acute and chronic treatment. J Pharmacol Exp Ther (1998) 284(1):75-82.
35. + pump via PKC dependent activation of NADPH oxidase. Am J Physiol Cell Physiol (2009) 296(4):C693-C700.
36. + pump regulation. Circ Res (2009) 105(2):185-193.
37. 1 pump subunit. Abst 12th International ATPase Conference (2008): Abs 157.
38. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN: The neurohumoral axis in congestive heart failure. Ann Intern Med (1984) 101(3):370-377. (Pubitemid 14033790)
39. Mudd JO, Kass DA: Tackling heart failure in the twenty-first century. Nature (2008) 451(7181):919-928.
40. Neubauer S: The failing heart - An engine out of fuel. N Engl J Med (2007) 356(11):1140-1151.
41. Insel PA, Head BP, Ostrom RS, Patel HH, Swaney JS, Tang CM, Roth DM: Caveolae and lipid rafts: G protein-coupled receptor signaling microdomains in cardiac myocytes. Ann N Y Acad Sci (2005) 1047:166-172.
42. Huang Y, Hunyor SH, Jiang L, Kawaguchi O, Shirota K, Ikeda Y, Yuasa T, Gallagher G, Zeng B, Zheng X: Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: Functional, energetic, structural, and cellular responses. Am J Physiol Heart Circ Physiol (2004) 286(6):H2141-H2150. (Pubitemid 38685228)
43. 3- adrenergic receptor stimulation in a canine model of ventricular tachycardia. Heart Rhythm (2008) 5(2):289-297.
44. Zhou S, Paz O, Cao JM, Asotra K, Chai NN, Wang C, Chen LS, Fishbein MC, Sharifi B, Chen PS: Differential β-adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia. Heart Rhythm (2005) 2(12):1347-1355. (Pubitemid 43055418)
45. 3-adrenergic receptor a new target for treatment of post-infarct ventricular tachyarrhythmias and prevention of sudden cardiac death? Heart Rhythm (2008) 5(2):298-299.
46. + concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. Cardiovasc Res (2003) 57(4):1035-1043.
47. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation (2002) 105(15):1797-1803. (Pubitemid 34408889)
48. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail (2003) 5(5):659-667. •• Presents data from the MOXCON study, which unexpectedly demonstrated that reducing the stimulation of the β3-AR increased mortality in patients with heart failure. By inference, the investigators suggested that receptor stimulation could be useful in the treatment of such patients; the study data were derived from a long-term study. (Pubitemid 38043972)
49. Coats AJ: Heart Failure 99 - the MOXCON story. Int J Cardiol (1999) 71(2):109-111.
50. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human β-adrenergic receptor subtypes - Characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (2004) 369(2):151-159. • Highlights the technical difficulties associated with defining clinically relevant β-AR affinities in vitro, and provides important selectivity and activity data for the human β3-AR. (Pubitemid 38270770)
51. Tomaselli GF, Zipes DP: What causes sudden death in heart failure? Circ Res (2004) 95(8):754-763. (Pubitemid 39390577)
52. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA (2007) 298(10):1189-1195. (Pubitemid 47403105)
53. Bidasee KR, Zheng H, Shao CH, Parbhu SK, Rozanski GJ, Patel KP: Exercise training initiated after the onset of diabetes preserves myocardial function: Effects on expression of β-adrenoceptors. J Appl Physiol (2008) 105(3):907-914.
54. 3-adrenergic receptors at a transcriptional level. Diabetes (2000) 49(12):2108-2115.
55. +-ATPases in ventricular myocytes. J Physiol Sci (2006) 56(1):113-121.
56. 3-adrenergic receptor agonists with good oral bioavailability. Part I. J Med Chem (2008) 51(6):1925-1944.
57. 3 adrenergic receptor agonists. J Med Chem (2006) 49(9):2758-2771.
58. 3- adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol (2009) 53(17):1532-1538.
59. Brixius K, Song Q, Malick A, Boelck B, Addicks K, Bloch W, Mehlhorn U, Schwinger RH: eNOS is not activated by nebivolol in human failing myocardium. Life Science (2006) 79(13): 1234-1241. (Pubitemid 44209171)
60. Brixius K, Bundkirchen A, Bölck B, Mehlhorn U, Schwinger RH: Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol (2001) 133(8):1330-1338. (Pubitemid 32783494)
61. Bundkirchen A, Nguyen Q, Brixius K, Bölck B, Mehlhorn U, Schwinger RH: Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium. Eur J Pharmacol (2003) 476(1-2):97-105. (Pubitemid 37315541)
62. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 307(4):205-211. (Pubitemid 12079105)
63. 3-adrenoceptors in the diabetic heart: Effects on nitric oxide signaling and forkhead transcription factor-3. Eur J Pharmacol (2008) 595(1-3):44-51.
64. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA et al: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation (2005) 112(12):e154-e235.
65. 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther (1996) 278(3):1435-1443.
66. 3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: A double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab (2007) 92(2):527-531.
67. 3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol (2008) 294(5):G1114-G1119. Reference to patent literature
68. 3-AR agonists, that are useful in the treatment of those mammals, and in particular humans, with conditions characterized by abnormalities of myocardial cell ion levels, including heart failure and myocardial hypertrophy.